|
1
|
Mody MD, Rocco JW, Yom SS, Haddad RI and
Saba NF: Head and neck cancer. Lancet. 398:2289–2299. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Barsouk A, Aluru JS, Rawla P, Saginala K
and Barsouk A: Epidemiology, risk factors, and prevention of head
and neck squamous cell carcinoma. Med Sci (Basel).
11:422023.PubMed/NCBI
|
|
4
|
Muzaffar J, Bari S, Kirtane K and Chung
CH: Recent advances and future directions in clinical management of
head and neck squamous cell carcinoma. Cancers (Basel). 13:3382021.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sánchez-Herrero E, Serna-Blasco R, Robado
de Lope L, González-Rumayor V, Romero A and Provencio M:
Circulating tumor DNA as a cancer biomarker: An overview of
biological features and factors that may impact on ctDNA analysis.
Front Oncol. 12:9432532022. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Caputo V, Ciardiello F, Corte CMD, Martini
G, Troiani T and Napolitano S: Diagnostic value of liquid biopsy in
the era of precision medicine: 10 Years of clinical evidence in
cancer. Explor Target Antitumor Ther. 4:102–138. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kogo R, Manako T, Iwaya T, Nishizuka S,
Hiraki H, Sasaki Y, Idogawa M, Tokino T, Koide A, Komune N, et al:
Individualized circulating tumor DNA monitoring in head and neck
squamous cell carcinoma. Cancer Med. 11:3960–3968. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Khan KH, Cunningham D, Werner B,
Vlachogiannis G, Spiteri I, Heide T, Mateos JF, Vatsiou A, Lampis
A, Damavandi MD, et al: Longitudinal liquid biopsy and mathematical
modeling of clonal evolution forecast time to treatment failure in
the PROSPECT-C phase II colorectal cancer clinical trial. Cancer
Discov. 8:1270–1285. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Abeni E, Grossi I, Marchina E, Coniglio A,
Incardona P, Cavalli P, Zorzi F, Chiodera PL, Paties CT, Crosatti
M, et al: DNA methylation variations in familial female and male
breast cancer. Oncol Lett. 21:4682021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Abeni E, Salvi A, Marchina E, Traversa M,
Arici B and De Petro G: Sorafenib induces variations of the DNA
methylome in HA22T/VGH human hepatocellular carcinoma-derived
cells. Int J Oncol. 51:128–144. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Markou Α, Londra D, Tserpeli V, Kollias I,
Tsaroucha E, Vamvakaris I, Potaris K, Pateras I, Kotsakis Α,
Georgoulias V and Lianidou Ε: DNA methylation analysis of tumor
suppressor genes in liquid biopsy components of early stage NSCLC:
A promising tool for early detection. Clin Epigenetics. 14:612022.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Schröck A, Leisse A, de Vos L, Gevensleben
H, Dröge F, Franzen A, Wachendörfer M, Schröck F, Ellinger J,
Teschke M, et al: Free-circulating methylated DNA in blood for
diagnosis, staging, prognosis, and monitoring of head and neck
squamous cell carcinoma patients: An observational prospective
cohort study. Clin Chem. 63:1288–1296. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sun J, Zheng MY, Li YW and Zhang SW:
Structure and function of Septin 9 and its role in human malignant
tumors. World J Gastrointest Oncol. 12:619–631. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Semaan A, van Ellen A, Meller S, Bergheim
D, Branchi V, Lingohr P, Goltz D, Kalff JC, Kristiansen G, Matthaei
H, et al: SEPT9 and SHOX2 DNA methylation status and its utility in
the diagnosis of colonic adenomas and colorectal adenocarcinomas.
Clin Epigenetics. 8:1002016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wasserkort R, Kalmar A, Valcz G, Spisak S,
Krispin M, Toth K, Tulassay Z, Sledziewski AZ and Molnar B:
Aberrant septin 9 DNA methylation in colorectal cancer is
restricted to a single CpG island. BMC Cancer. 13:3982013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Matsui S, Kagara N, Mishima C, Naoi Y,
Shimoda M, Shimomura A, Shimazu K, Kim SJ and Noguchi S:
Methylation of the SEPT9-v2 promoter as a novel marker for the
detection of circulating tumor DNA in breast cancer patients. Oncol
Rep. 36:2225–2235. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jiang Y, Liu L, Xiang Q, He X, Wang Y,
Zhou D, Zou C, Chen Q, Peng M, He J, et al: SEPT9-v2, frequently
silenced by promoter hypermethylation, exerts anti-tumor functions
through inactivation of Wnt/β-catenin signaling pathway via
miR92b-3p/FZD10 in nasopharyngeal carcinoma cells. Clin
Epigenetics. 12:412020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li Y, Song L, Gong Y and He B: Detection
of colorectal cancer by DNA methylation biomarker SEPT9: Past,
present and future. Biomark Med. 8:755–769. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Verdier-Pinard P, Salaun D, Bouguenina H,
Shimada S, Pophillat M, Audebert S, Agavnian E, Coslet S,
Charafe-Jauffret E, Tachibana T and Badache A: Septin 9_i2 is
downregulated in tumors, impairs cancer cell migration and alters
subnuclear actin filaments. Sci Rep. 7:449762017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhou X, Lu X, Wu H, Liu J and Huang H:
Diagnostic performance of SHOX2 promoter methylation as biomarker
for lung cancer identification: A meta-analysis update. Thorac
Cancer. 12:3327–3332. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Song L, Yu H and Li Y: Diagnosis of lung
cancer by SHOX2 gene methylation assay. Mol Diagn Ther. 19:159–167.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gao H, Yang J, He L, Wang W, Liu Y, Hu Y,
Ge M, Ding J and Ye Q: The diagnostic potential of SHOX2 and
RASSF1A DNA methylation in early lung adenocarcinoma. Front Oncol.
12:8490242022. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang YA, Zhou Y, Luo X, Song K, Ma X,
Sathe A, Girard L, Xiao G and Gazdar AF: SHOX2 is a potent
independent biomarker to predict survival of WHO grade II–III
diffuse gliomas. EBioMedicine. 13:80–89. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
de Vos L, Gevensleben H, Schröck A,
Franzen A, Kristiansen G, Bootz F and Dietrich D: Comparison of
quantification algorithms for circulating cell-free DNA methylation
biomarkers in blood plasma from cancer patients. Clin Epigenetics.
9:1252017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hindson CM, Chevillet JR, Briggs HA,
Gallichotte EN, Ruf IK, Hindson BJ, Vessella RL and Tewari M:
Absolute quantification by droplet digital PCR versus analog
real-time PCR. Nat Methods. 10:1003–1005. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Camuzi D, Buexm LA, Lourenço SQC, Esposti
DD, Cuenin C, Lopes MSA, Manara F, Talukdar FR, Herceg Z, Ribeiro
Pinto LF and Soares-Lima SC: HPV infection leaves a DNA methylation
signature in oropharyngeal cancer affecting both coding genes and
transposable elements. Cancers (Basel). 13:36212021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wiencke JK, Bracci PM, Hsuang G, Zheng S,
Hansen H, Wrensch MR, Rice T, Eliot M and Kelsey KT: A comparison
of DNA methylation specific droplet digital PCR (ddPCR) and real
time qPCR with flow cytometry in characterizing human T cells in
peripheral blood. Epigenetics. 9:1360–1365. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Van Wesenbeeck L, Janssens L, Meeuws H,
Lagatie O and Stuyver L: Droplet digital PCR is an accurate method
to assess methylation status on FFPE samples. Epigenetics.
13:207–213. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hindson BJ, Ness KD, Masquelier DA,
Belgrader P, Heredia NJ, Makarewicz AJ, Bright IJ, Lucero MY,
Hiddessen AL, Legler TC, et al: High-throughput droplet digital PCR
system for absolute quantitation of DNA copy number. Anal Chem.
83:8604–8610. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Manganelli M, Grossi I, Ferracin M,
Guerriero P, Negrini M, Ghidini M, Senti C, Ratti M, Pizzo C,
Passalacqua R, et al: Longitudinal circulating levels of
miR-23b-3p, miR-126-3p and lncRNA GAS5 in HCC patients treated with
sorafenib. Biomedicines. 9:8132021. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
van Ginkel JH, Huibers MMH, van Es RJJ, de
Bree R and Willems SM: Droplet digital PCR for detection and
quantification of circulating tumor DNA in plasma of head and neck
cancer patients. BMC Cancer. 17:4282017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Fung SYH, Chan KCA, Wong EWY, Ng CWK, Cho
R, Yeung ZWC, Lam JWK and Chan JYK: Droplet digital PCR of tumor
suppressor gene methylation in serial oral rinses of patients with
head and neck squamous cell carcinoma. Head Neck. 43:1812–1822.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Huang SH and O'Sullivan B: Overview of the
8th edition TNM classification for head and neck cancer. Curr Treat
Options Oncol. 18:402017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ku JL, Jeon YK and Park JG:
Methylation-specific PCR. Methods Mol Biol. 791:23–32. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Huang Z, Bassil CF and Murphy SK:
Methylation-specific PCR. Methods Mol Biol. 1049:75–82. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Manganelli M, Grossi I, Corsi J,
D'Agostino VG, Jurikova K, Cusanelli E, Molfino S, Portolani N,
Salvi A and De Petro G: Expression of cellular and extracellular
TERRA, TERC and TERT in hepatocellular carcinoma. Int J Mol Sci.
23:61832022. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Grossi I, Schiavone M, Cannone E, Grejdan
OA, Tobia C, Bonomini F, Rezzani R, Salvi A and De Petro G: Lasp1
expression is implicated in embryonic development of zebrafish.
Genes (Basel). 14:352022. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Vo TTL, Nguyen TN, Nguyen TT, Pham ATD,
Vuong DL, Ta VT and Ho VS: SHOX2 methylation in Vietnamese patients
with lung cancer. Mol Biol Rep. 49:3413–3421. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yu M, Carter KT, Makar KW, Vickers K,
Ulrich CM, Schoen RE, Brenner D, Markowitz SD and Grady WM:
MethyLight droplet digital PCR for detection and absolute
quantification of infrequently methylated alleles. Epigenetics.
10:803–809. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
de Vos L, Jung M, Koerber RM, Bawden EG,
Holderried TAW, Dietrich J, Bootz F, Brossart P, Kristiansen G and
Dietrich D: Treatment response monitoring in patients with advanced
malignancies using cell-free SHOX2 and SEPT9 DNA methylation in
blood: An observational prospective study. J Mol Diagn. 22:920–933.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Bergheim J, Semaan A, Gevensleben H,
Groening S, Knoblich A, Dietrich J, Weber J, Kalff JC, Bootz F,
Kristiansen G and Dietrich D: Potential of quantitative SEPT9 and
SHOX2 methylation in plasmatic circulating cell-free DNA as
auxiliary staging parameter in colorectal cancer: A prospective
observational cohort study. Br J Cancer. 118:1217–1228. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Crowley E, Di Nicolantonio F, Loupakis F
and Bardelli A: Liquid biopsy: Monitoring cancer-genetics in the
blood. Nat Rev Clin Oncol. 10:472–484. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Elazezy M and Joosse SA: Techniques of
using circulating tumor DNA as a liquid biopsy component in cancer
management. Comput Struct Biotechnol J. 16:370–378. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Stejskal P, Goodarzi H, Srovnal J, Hajdúch
M, van't Veer LJ and Magbanua MJM: Circulating tumor nucleic acids:
biology, release mechanisms, and clinical relevance. Mol Cancer.
22:152023. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Postel M, Roosen A, Laurent-Puig P, Taly V
and Wang-Renault SF: Droplet-based digital PCR and next generation
sequencing for monitoring circulating tumor DNA: A cancer
diagnostic perspective. Expert Rev Mol Diagn. 18:7–17. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Luo H, Wei W, Ye Z, Zheng J and Xu RH:
Liquid biopsy of methylation biomarkers in cell-free DNA. Trends
Mol Med. 27:482–500. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Krausewitz P, Kluemper N, Richter AP,
Büttner T, Kristiansen G, Ritter M and Ellinger J: Early dynamics
of quantitative SEPT9 and SHOX2 methylation in circulating
cell-free plasma DNA during prostate biopsy for prostate cancer
diagnosis. Cancers (Basel). 14:43552022. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Huang X, Duijf PHG, Sriram S, Perera G,
Vasani S, Kenny L, Leo P and Punyadeera C: Circulating tumour DNA
alterations: Emerging biomarker in head and neck squamous cell
carcinoma. J Biomed Sci. 30:652023. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Beltrán-García J, Osca-Verdegal R,
Mena-Mollá S and García-Giménez JL: Epigenetic IVD tests for
personalized precision medicine in cancer. Front Genet. 10:6212019.
View Article : Google Scholar : PubMed/NCBI
|
